Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said. The company won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets.
“Dry eye is too often the culprit of why patients drop out of contact lenses or why they may have a less than optimal outcome from their cataract surgery,” J&J Vision chairwoman Ashley McEvoy said in a press release.. “The medical device technologies from TearScience will allow us to address the main underlying cause of Dry Eye, giving us a mechanical solution to a mechanical problem.”
Johnson & Johnson said the acquisition was made via its recently acquired Abbott Medical Optics division.
In July, J&J said its medical device division is rolling its Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.